Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases. The company has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in December 2018. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone609-619-3990
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.09 million
Profitability
Miscellaneous
Employees56
Next Earnings Date12/17/2019 (Estimated)
OptionableNot Optionable
Outlook Therapeutics (NASDAQ:OTLK) Frequently Asked Questions
What is Outlook Therapeutics' stock symbol?
Outlook Therapeutics trades on the NASDAQ under the ticker symbol "OTLK."
When did Outlook Therapeutics' stock split? How did Outlook Therapeutics' stock split work?
Shares of Outlook Therapeutics reverse split before market open on Monday, March 18th 2019. The 1-8 reverse split was announced on Friday, March 15th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 15th 2019. An investor that had 100 shares of Outlook Therapeutics stock prior to the reverse split would have 13 shares after the split.
How were Outlook Therapeutics' earnings last quarter?
Outlook Therapeutics, Inc. (NASDAQ:OTLK) issued its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.13. The business earned $0.58 million during the quarter, compared to analysts' expectations of $0.73 million. View Outlook Therapeutics' Earnings History.
When is Outlook Therapeutics' next earnings date?
What price target have analysts set for OTLK?
5 analysts have issued 12-month price targets for Outlook Therapeutics' shares. Their predictions range from $4.00 to $12.00. On average, they anticipate Outlook Therapeutics' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 576.7% from the stock's current price. View Analyst Price Targets for Outlook Therapeutics.
What is the consensus analysts' recommendation for Outlook Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Outlook Therapeutics.
Has Outlook Therapeutics been receiving favorable news coverage?
Headlines about OTLK stock have trended somewhat positive this week, according to InfoTrie. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Outlook Therapeutics earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Outlook Therapeutics.
Who are some of Outlook Therapeutics' key competitors?
Some companies that are related to Outlook Therapeutics include Acorda Therapeutics (ACOR), Allena Pharmaceuticals (ALNA), Nantkwest (NK), Axcella Health (AXLA), Gamida Cell (GMDA), Jounce Therapeutics (JNCE), Novavax (NVAX), Aptose Biosciences (APTO), Adaptimmune Therapeutics (ADAP), Windtree Therapeutics (WINT), Vical (VICL), Fennec Pharmaceuticals (FENC), Brainstorm Cell Therapeutics (BCLI), Polarityte (PTE) and Idera Pharmaceuticals (IDRA).
What other stocks do shareholders of Outlook Therapeutics own?
Who are Outlook Therapeutics' key executives?
Outlook Therapeutics' management team includes the folowing people:
- Mr. Lawrence A. Kenyon, Pres, CEO, CFO, Company Sec., Treasurer & Director (Age 53)
- Dr. Pankaj Mohan, Founder & Director (Age 54)
- Dr. Kenneth M. Bahrt, Chief Medical Officer (Age 66)
- Mr. Terry Dagnon, Chief Operating Officer (Age 57)
- Rick Gregory, Director of Marketing & Communications
How do I buy shares of Outlook Therapeutics?
Shares of OTLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Outlook Therapeutics' stock price today?
One share of OTLK stock can currently be purchased for approximately $1.33.
How big of a company is Outlook Therapeutics?
Outlook Therapeutics has a market capitalization of $37.55 million and generates $3.09 million in revenue each year. The company earns $-30,090,000.00 in net income (profit) each year or ($10.80) on an earnings per share basis. Outlook Therapeutics employs 56 workers across the globe.View Additional Information About Outlook Therapeutics.
What is Outlook Therapeutics' official website?
How can I contact Outlook Therapeutics?
Outlook Therapeutics' mailing address is 7 CLARKE DRIVE, CRANBURY NJ, 08512. The company can be reached via phone at 609-619-3990 or via email at [email protected]
MarketBeat Community Rating for Outlook Therapeutics (NASDAQ OTLK)
MarketBeat's community ratings are surveys of what our community members think about Outlook Therapeutics and other stocks. Vote "Outperform" if you believe OTLK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTLK will underperform the S&P 500 over the long term. You may vote once every thirty days.
